BioSpace News Archive

Award is one of the highest honors in the category of field service, recognizing commitment to outstanding innovation, leadership and excellence

MediciNova, Inc. announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 for the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the third quarter ended September 28, 2019.

Magellan Health, Inc. announced that it will report its earnings for the third quarter ended on September 30, 2019 at approximately 6:30 a.m. Eastern on Friday, November 1, 2019. At 8:00 a.m.

Sharps Compliance Corp. reported financial results for the first quarter of fiscal year 2020, ended September 30, 2019.

Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF) (“Aleafia Health” or the “Company”) will announce its 2019 Third Quarter Financial Results on November 12, 2019 prior to market open.

FibroGen, Inc. (NASDAQ: FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with unresectable locally advanced pancreatic cancer (LAPC).

Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced preliminary data from an expanded access study administering investigational AXO-AAV-GM2 gene therapy in two patients with infantile Tay-Sachs disease (TSD) at the 27th Annual Congress of the European Society of Gene and Cell Therapy.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 10,449,203 to the Company on October 22, 2019.

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today a collaboration with the Weizmann Institute of Science to develop a selective treatment against antibiotic resistant strains of Staphylococcus aureus infection, in a microbiome focused approach